Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b clinical study of budoprutug for SLE

Next Previous
X
Search
Trial Profile

A Phase 1b clinical study of budoprutug for SLE

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budoprutug (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions

    • Most Recent Events

    • 19 Nov 2024 New trial record
    • 12 Nov 2024 According to a Climb Bio media release, the company has now received the clearance of our IND for our Phase 1b clinical trial of budoprutug in SLE, and plans to initiate this Phase 1b clinical study in the first half of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top